Skip to content
OpenCapital
Get started

Utah Medical Products UTMD Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments at other companies

Belden logo
BeldenBDC
0.2%-0.1pp
Capital City Bank Group logo
Capital City Bank GroupCCBG
2.6%-0.4pp
CTO
Citius Oncology, Inc.CTOR
0%—
Cineverse Corp. logo
Cineverse Corp.CNVS
0%—
Quantum Computing Inc. logo
Quantum Computing Inc.QUBT
0%—
Norwood Financial logo
Norwood FinancialNWFL
4.5%0.0pp

Other financials

Income statement

See full
Revenue$8.7M-10.2%
Gross profit$5.3M-4.6%
Operating income$2.6M-18.6%
Net income$2.6M-14.4%
EPS (diluted)$0.82-10.9%

Balance sheet

See full
Cash & equivalents$87.4M+4.9%
Total debt$210.0K—
Total equity$120.4M+2.8%
Total assets$124.4M+1.5%

Cash flow

See full
Operating cash flow$3.1M-30.4%
CapEx$130.0K-29.3%
Free cash flow$3.0M-30.4%

Valuation

See full
Market cap$219.63M+26.4%
Enterprise value$132.44M+42.5%
P/E20.3×+6.4×
P/S5.9×+1.4×

Profitability

See full
Gross margin57.9%-0.4pp
Operating margin28.8%-3.9pp
Net margin28.9%-4.1pp
FCF margin34.7%0.0pp

Returns & leverage

See full
Return on equity9.1%-1.4pp
Debt / equity0×—
Current ratio28.6×+6.3×

Where this comes from

Reported directly by Utah Medical Products in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments.

The official record: Utah Medical Products’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's share based compensation arrangement by share based payment award fair value assumptions expected dividend payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Utah Medical Products's share based compensation arrangement by share based payment award fair value assumptions expected dividend payments?
Utah Medical Products (UTMD) reported share based compensation arrangement by share based payment award fair value assumptions expected dividend payments of $0.08 in Q4 2025.
How has Utah Medical Products's share based compensation arrangement by share based payment award fair value assumptions expected dividend payments changed year-over-year?
Utah Medical Products's share based compensation arrangement by share based payment award fair value assumptions expected dividend payments increased by 3.2% year-over-year, from $0.08 to $0.08.
What is the long-term trend for Utah Medical Products's share based compensation arrangement by share based payment award fair value assumptions expected dividend payments?
Over 3 years (2022 to 2025), Utah Medical Products's share based compensation arrangement by share based payment award fair value assumptions expected dividend payments has grown at a 2.1% compound annual growth rate (CAGR), from $0.31 to $0.33.
What does share based compensation arrangement by share based payment award fair value assumptions expected dividend payments mean?
The expected dividend payments per share used as a key input in the valuation models for employee stock options. This assumption reflects the company's anticipated dividend policy over the expected term of the options. It is a critical factor in determining the fair value of share-based compensation expenses.